Esperion Therapeutis.Inc. buy Heureka
Summary
This prediction ended on 10.02.20 with a price of €60.54. The BUY prediction by Heureka finished with a performance of 15.67%. Heureka has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Esperion Therapeutis.Inc. | -14.715% | -14.715% | 43.411% | -88.055% |
iShares Core DAX® | 0.192% | 3.121% | 16.828% | 19.649% |
iShares Nasdaq 100 | 1.245% | 5.051% | 31.022% | 56.928% |
iShares Nikkei 225® | -0.992% | 1.101% | 9.804% | 6.691% |
iShares S&P 500 | 0.154% | 2.864% | 26.511% | 47.657% |
Comments by Heureka for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.
Stopped prediction by Heureka for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
26.02.20
09.03.20
09.03.20